| 5.78 0.14 (2.48%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.28 | 1-year : | 8.51 |
| Resists | First : | 6.23 | Second : | 7.28 |
| Pivot price | 5.66 |
|||
| Supports | First : | 5.35 | Second : | 4.8 |
| MAs | MA(5) : | 5.85 |
MA(20) : | 5.52 |
| MA(100) : | 5.75 |
MA(250) : | 4.17 |
|
| MACD | MACD : | 0.1  |
Signal : | 0 |
| %K %D | K(14,3) : | 65.7 |
D(3) : | 73.8 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 7 | Low : | 1.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SVRA ] has closed below upper band by 39.2%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.89 - 5.92 | 5.92 - 5.95 |
| Low: | 5.6 - 5.63 | 5.63 - 5.66 |
| Close: | 5.73 - 5.78 | 5.78 - 5.83 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Sat, 18 Apr 2026
Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why - MarketBeat
Fri, 17 Apr 2026
Savara Announces New Employment Inducement Grant - ChartMill
Fri, 17 Apr 2026
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Fri, 17 Apr 2026
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st
Thu, 16 Apr 2026
Savara (SVRA) Receives FDA Review Extension for Molgramostim App - GuruFocus
Thu, 16 Apr 2026
Savara gets FDA review extension for lead asset (SVRA:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 205 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 97.5 (%) |
| Shares Short | 23,510 (K) |
| Shares Short P.Month | 22,140 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33 % |
| Return on Equity (ttm) | -63.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -101 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -10.91 |
| PEG Ratio | 0 |
| Price to Book value | 7.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|